Head-to-head
Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
A side-by-side comparison: pricing, clinical oversight, medications, state availability, and which program is the better fit for which patient.
| Dimension | Hims & Hers | Noom Med |
|---|---|---|
| Starting price | $145–$165/mo | $70/mo |
| Pricing range | $199–$299/mo | $70/mo app + medication |
| Compounded GLP-1 | ✓ Yes | ✓ Yes |
| Brand-name (Wegovy/Zepbound) | ✗ No | ✓ Yes |
| Insurance pathway | ✗ No (cash-pay) | ✗ No (cash-pay) |
| Medical Director model | Network of NPs and physicians | Network clinicians |
| States available | Reports broad U.S. availability | Most US states |
| Founded | 2017 | 2008 |
| Editorial score | 78/100 | 71/100 |
Hims & Hers starts at $145–$165/mo. Noom Med starts at $70/mo. Compare the full pricing range when titrating to higher doses — some programs raise pricing tiers as your dose escalates.
Hims & Hers operates under Network of NPs and physicians. Noom Med operates under Network clinicians. Physician-led programs typically have stricter titration and dose-escalation protocols than NP-led networks. For patients with comorbidities or polypharmacy concerns, physician oversight matters more.
Hims & Hers prescribes: Compounded semaglutide, Compounded liraglutide.
Noom Med prescribes: Compounded semaglutide, Wegovy, Zepbound.
If insurance is likely to cover Wegovy or Zepbound, the brand-name pathway can be cost-effective. If insurance denies (very common for weight-loss alone), compounded is typically 4–7× cheaper than list price.
Hims & Hers starts at $145–$165/mo ($199–$299/mo). Noom Med starts at $70/month ($70/mo app + medication).
Both programs prescribe compounded semaglutide and/or tirzepatide. NexLife and Henry Meds are compounded-only. Ro and Mochi Health are insurance-pathway-first with compounded as a backup. Hims is compounded-focused with NP-led oversight.
Insurance pathway support: Hims & Hers — No (cash-pay). Noom Med — No (cash-pay).
Hims & Hers clinical model: Network of NPs and physicians. Noom Med clinical model: Network clinicians. Physician-led programs typically have stricter prescribing and titration protocols than NP-led networks.
Hims & Hers: Reports broad U.S. availability. Noom Med: Most US states.
NexLife is one editorial pick for patients prioritizing published cash-pay pricing and physician-led oversight. Read our individual reviews of Hims & Hers and Noom Med for full context.
Hims & Hers: Solid mass-market option. Strong app, weaker on clinical depth than physician-led peers.
Noom Med: Strong app, weaker as a pure GLP-1 program.